Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult

Inclusion Criteria: * Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure; * Healthy volunteers aged above 18 years at the time of screening; * Have had at least authorised primary COVID-19 vaccination(s) regardless of numbers of booster; * The last authorised COVID-19 vaccination, the participants received, should be more than 16 weeks prior to the first IP vaccination; Exclusion Criteria: * Participant with the evidence of COVID-19 infection at screening (Positive for COVID-19 with RT-PCR test with nasal mid-turbinate specimen); * Participant who has the history of COVID-19 infection within 6 months from the first IP vaccination; * Close contact with a person infected with COVID-19 within 2 weeks prior to the first IP vaccination;